{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:05:52Z","timestamp":1790165152213,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2026.1977379","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:46:48Z","timestamp":1790164008000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Editorial: Cannabidiol: perspectives on drug-resistant epilepsy management"],"prefix":"10.3389","volume":"17","author":[{"given":"Jer\u00f3nimo A.","family":"Auzmendi","sequence":"first","affiliation":[{"name":"Instituto de Neurociencias de Castilla y Leon","place":["Salamanca, Spain"]},{"name":"School of Pharmacy and Biochemistry, Institute of Pharmacological Research (ININFA- UBA-CONICET), University of Buenos Aires","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gil-Nagel","sequence":"additional","affiliation":[{"name":"Director of Epilepsy Unit, Hospital Ruber Internacional","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores E.","family":"L\u00f3pez Garc\u00eda","sequence":"additional","affiliation":[{"name":"Instituto de Neurociencias de Castilla y Leon","place":["Salamanca, Spain"]},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL)","place":["Salamanca, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lazarowski","sequence":"additional","affiliation":[{"name":"Instituto de Neurociencias de Castilla y Leon","place":["Salamanca, Spain"]},{"name":"School of Pharmacy and Biochemistry, Institute for Research in Physiopathology and Clinical Biochemistry (INFIBIOC)","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100692","DOI":"10.37349\/en.202M00692","article-title":"Ferroptosis: is it both cause and effect in refractory epilepsy?","volume":"4","author":"Auzmendi","year":"2025","journal-title":"Explor Neurosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fnbeh.2020.00032","article-title":"Cannabidiol (CBD) inhibited rhodamine-123 efflux in cultured vascular endothelial cells and astrocytes under hypoxic conditions","volume":"14","author":"Auzmendi","year":"2020","journal-title":"Front. Behav. Neurosci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.seizure.2021.11.020","article-title":"High dose cannabidiol (CBD) in the treatment of new-onset refractory status epilepticus (NORSE)","volume":"94","author":"Aydemir","year":"2022","journal-title":"Seizure"},{"key":"B4","article-title":"Systemic inflammatory response syndrome","volume-title":"Statpearls. Treasure Island (FL)","author":"Baddam","year":"2025"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.16093","article-title":"Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy","volume":"60","author":"Birnbaum","year":"2019","journal-title":"Epilepsia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.seizure.2022.01.001","article-title":"Longterm use of cannabidiol-enriched medical cannabis in a prospective cohort of children with drug-resistant developmental and epileptic encephalopathy","volume":"95","author":"Caraballo","year":"2022","journal-title":"Seizure"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/ane.13305","article-title":"Cannabidiol efficacy independent of clobazam: meta-analysis of four randomized controlled trials","volume":"142","author":"Devinsky","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"B9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.seizure.2022.11.006","article-title":"Cannabidiol in refractory status epilepticus: a review of clinical experiences","volume":"103","author":"Duda","year":"2022","journal-title":"Seizure"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.eplepsyres.2016.10.012","article-title":"Bruno blanch New model of pharmacoresistant seizures induced by 3-mercaptopropionic acid in mice","volume":"129","author":"Enrique","year":"2017","journal-title":"Epilepsy Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1626054","DOI":"10.3389\/fphar.2025.1626054","article-title":"Analysis of six CYP450 genetic variants regarding the response to cannabidiol combined with anticonvulsant medication in mexican patients with drug-resistant epilepsy","volume":"16","author":"Feria-Romero","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3390\/brainsci16080851","article-title":"Subchronic cannabidiol (CBD) treatment during the silent period fails to prevent increased seizure susceptibility following lithium-pilocarpine-induced status epilepticus","volume":"16","author":"G\u00f3mez","year":"2026","journal-title":"Brain Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e43022","DOI":"10.1371\/journal.pone.0043022","article-title":"Pro-inflammatory cytokine regulation of P-glycoprotein in the developing blood-brain barrier","volume":"7","author":"Iqbal","year":"2012","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/epi.12271","article-title":"A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches","volume":"54","author":"Janigro","year":"2013","journal-title":"Epilepsia"},{"key":"B36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/pharmaceutics16010140","article-title":"An intravenous pharmacokinetic study of cannabidiol solutions in piglets through the application of a validated ultra-high-pressure liquid chromatography coupled to tandem mass spectrometry method for the simultaneous quantification of CBD and Its carboxylated metabolite in plasma","volume":"16","author":"Koch","year":"2024","journal-title":"Pharmaceutics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s12640-026-00826-x","article-title":"Differential effects of cannabidiol and cannabigerol on cognition, neuroinflammation, and blood-brain barrier integrity in a rat model of iron overload","volume":"44","author":"Kowalski","year":"2026","journal-title":"Neurotox Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1023\/b:cemn.0000012726.43842.d2","article-title":"Neuronal and glial expression of the multidrug resistance gene product in an experimental epilepsy model","volume":"24","author":"Lazarowski","year":"2004","journal-title":"Cell Mol. Neurobiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3389\/fnins.2019.00721","article-title":"Ferroptosis induction in pentylenetetrazole kindling and pilocarpine-induced epileptic seizures in mice","volume":"13","author":"Mao","year":"2019","journal-title":"Front. Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/epi.1693","article-title":"The long-term efficacy of cannabidiol in the treatment of refractory epilepsy","volume":"62","author":"Patel","year":"2021","journal-title":"Epilepsia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.seizure.2025.08.023","article-title":"Modulation of neuroinflammation as a therapeutic strategy for the control of epilepsy","volume":"131","author":"Ramos","year":"2025","journal-title":"Seizure"},{"key":"B24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.2174\/1570159X21666221117152249","article-title":"Inflammation as treatment target for status epilepticus","volume":"21","author":"Rejdak","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e09668","DOI":"10.1002\/advs.202509668","article-title":"Refractory status epilepticus and therapeutic uncertainties: a comprehensive review on targeting neuroinflammation and rationale for developing a platform trial","volume":"12","author":"Samarasekera","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/evj.13923","article-title":"Pharmacokinetics and oral bioavailability of cannabidiol in horses after intravenous and oral administration with oil and micellar formulations","volume":"55","author":"S\u00e1nchez de Medina","year":"2023","journal-title":"Equine Vet J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s12264-025-01348-w","article-title":"The role of neuroinflammation and network anomalies in drug-resistant epilepsy","volume":"41","author":"Shi","year":"2025","journal-title":"Neurosci. Bull."},{"key":"B27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/epi4.12684","article-title":"Systemic inflammation as a biomarker of seizure propensity and a target for treatment to reduce seizure propensity","volume":"8","author":"Stredny","year":"2023","journal-title":"Epilepsia Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with lennox-gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on cannabidiol treatment for drug-resistant seizures in Tuberous sclerosis complex: a placebo-controlled randomized clinical trial","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10787-021-00901-z","article-title":"Anti-inflammatory potential of cannabidiol (CBD) on combination of caecal slurry, LPS, and E. Coli-induced systemic inflammatory response syndrome (SIRS) in sprague dawley rats","volume":"30","author":"Trivedi","year":"2022","journal-title":"Inflammopharmacology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"106771","DOI":"10.1016\/j.phrs.2023.106771","article-title":"Sigma-1 receptor and seizures","volume":"191","author":"Vavers","year":"2023","journal-title":"Pharmacol. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41582-019-0217-x","article-title":"Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy","volume":"15","author":"Vezzani","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/cpdd.1262","article-title":"Pharmacokinetic drug-drug interaction with coadministration of cannabidiol and everolimus in a phase 1 healthy volunteer trial. Clin. Pharmacol","volume":"12","author":"Wray","year":"2023","journal-title":"Drug Dev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"103202","DOI":"10.1016\/j.etap.2019.103202","article-title":"Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model","volume":"70","author":"Xu","year":"2019","journal-title":"Environ Toxicol Pharmacol"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1977379\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:46:49Z","timestamp":1790164009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1977379\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":35,"alternative-id":["10.3389\/fphar.2026.1977379"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1977379","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1977379"}}